Release Date: October 31, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: What percent of XPHOZAH sales are not part of the Medicare bundle, and how do you plan to expand your product portfolio? Also, when do you expect IBSRELA to reach $1 billion in sales? A: Approximately 40% of XPHOZAH sales are non-Medicare. We are exploring expansion opportunities, led by Mike Kelleher, leveraging our strong balance sheet. As for IBSRELA, it's too early to specify a timeline for reaching $1 billion in sales, especially since we just completed our sales team expansion.
Q: What are the commercial strategies for XPHOZAH in 2025, and why does the IBSRELA guidance seem conservative? A: We aim for physicians to continue prescribing XPHOZAH based on clinical need, regardless of Medicare coverage changes. The IBSRELA guidance reflects our cautious approach, but we are optimistic due to the recent sales team expansion and positive feedback from the American College of Gastroenterology meeting.
Q: Can you elaborate on your plans for educating prescribers about XPHOZAH ahead of January 1, and how are you engaging with payers? A: We are advising prescribers to maintain their current practices, emphasizing the clinical benefits of XPHOZAH. Our communication with payers remains consistent, focusing on ensuring patient access through our ArdelyxAssist program.
Q: Have you made any progress with the injunction to temporarily halt the inclusion of oral therapies in the dialysis bundle for 2025? A: We hope for a court decision on the injunction before the end of the year, but there are no additional insights to provide at this time.
Q: What feedback are you receiving from doctors about XPHOZAH usage, and how are they utilizing it for their patients? A: Physicians are using XPHOZAH on-label alongside binders and are seeing significant results in patients who are not well-managed on binders alone. This feedback reinforces our confidence in XPHOZAH's potential.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.